Other

Maruha Corporation

Osaka Bioscience Institute

Japan Science and Technology Corporation

Maruha Nichiro Seafoods, Inc.

Japan As Represented by Director General of National Institute of Health Sciences

Kosuke Seiki

Hiroshi Oda

Yoshihiro Urade

Nobuyuki Sato

Hiroshi Nakajima

Naomi Eguchi

Masazumi Nishikawa

Yoshio Uehara

Hiroshi Akiyama

Fumitaka Saji

Hisashi Yoshioka

Teruo Inoue

Satoru Takeda

Nobuhito Hirawa

Tamio Maitani

Yutaka Eguchi

Yasuhiko Shiina

Mitsuhito Mase

Hiroya Nakau

Takashi Inui

A method for accurate and precise measurement of target proteins such as food allergen proteins in the specific foods is provided. The method is a method for immunological measurement of a food allergen protein in a processed food using an antibody against the food allergen protein, comprising adding animal tropomyosin to an assay solution upon measurement.

Highly sensitive method for detecting protein in food

Provided are: a method for predicting the onset of pregnancy-induced hypertension (PIH) by precisely detecting abnormalities that occur before the onset of PIH (where such abnormalities have been impossible to detect by various conventional testing methods for PIH) while imposing less of a burden on a subject; a method for evaluating a fetus and placental functions in PIH; and a method for detecting PIH, which comprises measuring the level of human lipocalin-type prostaglandin D synthase (L-PGDS) in a body fluid sample collected from a subject.

Method for predicting pregnancy-induced hypertension

The present invention relates to methods for differentiating demential diseases comprising measuring the concentration of human lipocalin-type prostaglandin D synthase in a sample of a body fluid collected from a subject and kits for differentiating demential diseases comprising an antibody specific to human lipocalin-type prostaglandin D synthase.

Methods to facilitate diagnosis of normal pressure hydrocephalus

The present invention relates to a method of detection of an early-stage renal disease, comprising determining the concentration of human lipocalin-type prostaglandin D synthase in a body fluid sample taken from a subject and comparing the determined concentration with a reference value set by determining the concentrations of human lipocalin-type prostaglandin D synthase in body fluid samples taken from healthy subjects; and a method of disease state management for a renal disease, comprising determining the concentration of human lipocalin-type prostaglandin D synthase in a body fluid sample taken from a subject and evaluating the glomerular filtration ability of the subject from the determined concentration.

Method of detection and disease state management for renal diseases

The present invention provides a method for predicting restenosis following coronary intervention by measuring human lipocalin-type prostaglandin D synthase (L-PGDS) in a body fluid sample. More particularly, this method comprises measuring the L-PGDS concentration in the sample and predicting restenosis following coronary intervention by using a change therein as an indicator.

Method for restenosis following coronary vessel intervention

The invention relates to a monoclonal antibody specifically recognizing lipocalin-type prostaglandin D synthase (L-PGDS), a hybridoma producing the monoclonal antibody, methods for detection of L-PGDS or diseases by the monoclonal antibody, and a kit for detection of L-PGDS by the monoclonal antibody. According to the invention, there is provided a monoclonal antibody specific to L-PGDS.

Prostaglandin D synthase-specific monoclonal antibody

The present invention provides a method for detecting or predicting ischemic disorders in a subject by using as an indication the concentration of human lipocalin-type prostaglandin D synthase (hPGDS) in body fluid samples from the subject. More specifically, the method comprises comparing the hPGDS concentrations in the body fluid samples from a subject with the reference values established for a normal subject, thereby detecting or predicting the ischemic disorders.

Methods and kits for detecting or predicting ischemic disorders

Growing community of inventors

Ibaraki, Japan

Kosuke Seiki